Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00343525 · ClinicalTrials.gov registry record · Phase 1
Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C
A Phase 1 study, sponsored by Peregrine Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00343525 is a Phase 1 study that has completed, run by Peregrine Pharmaceuticals. The registered enrollment target is 24 participants.
The verdict
NCT00343525, a Phase 1 study, has completed, sponsored by Peregrine Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of bavituximab when administered via an arm vein as multiple infusions and to examine how bavituximab behaves in the body and how it effects the amount of hepatitis C virus and immune modulators in individuals with chronic infection.
Interventions
- DRUG bavituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2006-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00343525
The ClinicalTrials.gov registry entry for NCT00343525 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Peregrine Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bavituximab is the first listed.
NCT00343525 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00343525 about?
NCT00343525 is a clinical study titled "Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C". The purpose of this study is to determine the safety and tolerability of bavituximab when administered via an arm vein as multiple infusions and to examine how bavituximab behaves in the body and how it effects the amount of hepatitis C virus and immune modulators in individuals with chronic infecti...
What is the current status of trial NCT00343525?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2006-05.
What interventions are being tested in trial NCT00343525?
The interventions under investigation include: bavituximab (DRUG).
Who is sponsoring clinical trial NCT00343525?
This trial is sponsored by Peregrine Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.